Ownership history in Frazier Life Sciences Management, L.P. · 12 quarters on record
This page tracks every 13F SEC filing in which Frazier Life Sciences Management, L.P. reported a position in BRIDGEBIO PHARMA INC (BBIO). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q4 | REDUCED | 3,545,557 | -299,900 | -7.8% | 7.28% | $271.2M | $76.49 |
| 2025 Q3 | ADDED | 3,845,457 | +45,000 | +1.2% | 5.98% | $199.7M | $51.94 |
| 2025 Q2 | UNCHANGED | 3,800,457 | — | 0% | 6.56% | $164.1M | $43.18 |
| 2025 Q1 | UNCHANGED | 3,800,457 | — | 0% | 6.00% | $131.4M | $34.57 |
| 2024 Q4 | ADDED | 3,800,457 | +40,000 | +1.1% | 4.33% | $104.3M | $27.44 |
| 2024 Q3 | ADDED | 3,760,457 | +127,853 | +3.5% | 3.84% | $95.7M | $25.46 |
| 2024 Q2 | ADDED | 3,632,604 | +217,000 | +6.4% | 4.30% | $92.0M | $25.33 |
| 2024 Q1 | ADDED | 3,415,604 | +689,655 | +25.3% | 4.46% | $105.6M | $30.92 |
| 2023 Q4 | UNCHANGED | 2,725,949 | — | 0% | 5.88% | $110.0M | $40.37 |
| 2023 Q3 | ADDED | 2,725,949 | +737,073 | +37.1% | 4.77% | $71.9M | $26.37 |
As of 2025 Q4 — sorted by position size